摘要
目的探讨吡格列酮联合多烯磷脂酰胆碱(Polyene phosphatidylcholine,PPC)治疗2型糖尿病(T2DM)合并非酒精性脂肪性肝病(Non-alcoholic fatty liver disease,NAFLD)患者的效果。方法选择2018年9月至2022年4月本院收治的T2DM合并NAFLD患者84例,随机分为单一组和联合组各42例,单一组给予吡格列酮治疗,联合组在对照组基础上辅以PPC治疗,比较两组临床疗效、肝纤维化指标、胰岛素功能、不良反应。结果治疗3个月后,联合组总有效率较单一组高(P<0.05);联合组HA、Ⅳ-C、LN、PCⅢ均较单一组低(P<0.05);联合组HOMA-IR、FINS较单一组低,HOMA-β较单一组高(P<0.05);联合组不良反应发生率与对照组比较差异无统计学意义(P>0.05)。结论吡格列酮与PPC联合治疗疗效较好,能够提高T2DM合并NAFLD患者胰岛素功能,抑制肝纤维化进展,且不增加不良反应发生率。
Objective To investigate the effect of pioglitazone combined with polyene phosphatidylcholine(PPC)in the treatment of type 2 diabetes mellitus(T2DM)patients with non-alcoholic fatty liver disease(NAFLD).Methods From September 2018 to April 2022,84 patients with T2DM complicated with NAFLD in our hospital were selected and divided into single group and combined group randomly,with 42 cases in each group.The single group was treated with pioglitazone,and the combined group was treated with PPC on the basis of the single group.The clinical efficacy,liver fibrosis indexes,insulin function and adverse reactions of the two groups were compared.Results After 3 months of treatment,the total effective rate of combined group was higher than that of single group(P<0.05).The HA,Ⅳ-C,LN and PCⅢof the combined group were lower than those of the single group(P<0.05).The HOMA-IR and FINS were lower and HOMA-βwas higher in the combined group than in the single group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion Pioglitazone combined with PPC is effective in the treatment of T2DM patients with NAFLD.It can improve insulin function,inhibit the progression of liver fibrosis,and does not increase the incidence of adverse reactions.
作者
张金艳
马洪德
庞国宏
ZHANG Jin-yan;MA Hong-de;PANG Guo-hong(Department of Infectious Diseases,Pingdingshan First People's Hospital,Pingdingshan 467000,Henan,China)
出处
《青岛医药卫生》
2023年第2期107-110,共4页
Qingdao Medical Journal
